If you are using an ESA (erythropoiesis stimulating agent) for the treatment of your anemia-condition, you are consuming a biologic drug. It means that such an ESA was created from living things’ building blocks, such as animals and plants, as the word bio, actually means life. Want to know about what does a kidney stone look like?
To manufacture biologic drugs are very expensive, whilst it is complex to create. This causes difficulty in obtaining it for many individuals who requires a biologic drug. The FDA (Food and Drug Administration) in the US now allows drug companies to create biosimilar medication.
The word similar in biosimilar drugs, refers to the fact that such a drug must be almost alike the original biologic product which is effective and safe to use. Copying an original biologic medication can be compared to copying an aspirin. There are certain differences in every batch of biologic as well as biosimilar drugs. This occurs because both kinds of drugs are created from living things. However, it is small differences and should not according to the law, have any affect on the efficacy or safety of the drug.
Similarly you can opt to purchase a more affordable aspirin brand rather than to buy the brand name, for example aspirin. Likewise you can purchase a more affordable biosimilar drug. This cheaper option should not be due to inferior quality, but due to the fact that expensive research about creating the original drug, was already conducted.
Biosimilar drugs were successfully used for a lot of years in Europe as well as other countries. Problems which are encountered with biosimilar drugs are usually experienced in countries where there are ineffective control over the manufacturing of the drugs. The FDA ensures that drug companies follow strict rules for creating effective and safe biosimilar drugs.
It took years of research by proverbially hundreds of scientists in this medical field, before the United States allowed biosimilar drugs. Presently the FDA is reviewing two new kinds of biosimilar ESA’s, which will be used in kidney dialysis. When these ESA’s are approved you may be able to receive a biosimilar drug for treating your condition of anemia soon.
Questions you may ask your medical professional include:
- Will my ESA medication change? You can request your medical
practitioner to inform you about any considered changes in your
medications, prior to its creation.
- What is the new medicine’s brand name? To enable you to update
your medication list at home, write it down and as information for
your additional medical practitioners.
- Whether any known side effects or reactions exist.
As applicable to all other drugs, safety is the most important factor. The issues regarding safety of which you should be clued up, are similar as for other medications, which includes the original biologic drugs:
- Side effects and allergic reactions: Your body may experience both
biologic as well as biosimilar drugs to be dangerous and may in turn react with different symptoms and signs. When you feel unwell after taking any drug it is important to inform your healthcare team, instantly. Observe signs such as swelling, itching, fever, sweating, a difficulty to breathe, muscle- or headaches, vomiting, nausea, diarrhea and all other changes which you experience or see in your body
- When your usual drugs are changed, which include:
Switching from original biologic ESA to biosimilar-ESA
Switching back from biosimilar ESA to original biologic ESA
Switching from one biosimilar ESA-brand to another brand
Switching from original biologic ESA-brand to another original biologic
Request your healthcare team to inform you about plans to change your medications, prior to the change. Enquire whether these changes were added to your medical record, together with the exchanged drugs’ complete brands (names). If you have the proper names of the product, it is easier to trace, should a problem occur.
Another vital issue is the effective functioning of a biosimilar ESA. This will be determined by the close monitoring of your healthcare team regarding you condition of anemia when you begin with the biosimilar ESA. Another point which counts is whether you inform the healthcare team about the feeling you are experiencing after changes had been made in your medications.
Biosimilar drugs will likewise generic drugs, allow more patients to receive the necessary care they require. As in the case of any other kind of drug, both patients and their healthcare teams firstly need to be aware about safety. Always enquire which medications you are receiving and the reason for it. This is the same where biosimilar drugs are concerned. Always inform your healthcare team about the feeling you are experiencing after changes had been made in your drug-prescriptions.